These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 7787250)

  • 1. p53 mutations in bladder carcinoma cell lines.
    Cooper MJ; Haluschak JJ; Johnson D; Schwartz S; Morrison LJ; Lippa M; Hatzivassiliou G; Tan J
    Oncol Res; 1994; 6(12):569-79. PubMed ID: 7787250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status.
    Maas S; Warskulat U; Steinhoff C; Mueller W; Grimm MO; Schulz WA; Seifert HH
    Urology; 2004 Feb; 63(2):392-7. PubMed ID: 14972509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome.
    Malkin D; Chilton-MacNeill S; Meister LA; Sexsmith E; Diller L; Garcea RL
    Oncogene; 2001 Jul; 20(33):4441-9. PubMed ID: 11494139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 gene mutations in human gastric cancer: wild-type p53 but not mutant p53 suppresses growth of human gastric cancer cells.
    Matozaki T; Sakamoto C; Suzuki T; Matsuda K; Uchida T; Nakano O; Wada K; Nishisaki H; Konda Y; Nagao M
    Cancer Res; 1992 Aug; 52(16):4335-41. PubMed ID: 1322785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.
    Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM
    J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exogenous mutant p53 DNA enhanced cisplatin-induced apoptosis in TSGH-8301 human bladder cancer cells.
    Chang FL; Ling YF; Lai MD
    Anticancer Res; 2000; 20(1A):329-36. PubMed ID: 10769676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines.
    Liu Y; Bodmer WF
    Proc Natl Acad Sci U S A; 2006 Jan; 103(4):976-81. PubMed ID: 16418264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The p53 tumor suppressor gene and gene product.
    Levine AJ
    Princess Takamatsu Symp; 1989; 20():221-30. PubMed ID: 2488233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations in p53 are frequent in the preneoplastic stage of mouse mammary tumor development.
    Jerry DJ; Ozbun MA; Kittrell FS; Lane DP; Medina D; Butel JS
    Cancer Res; 1993 Jul; 53(14):3374-81. PubMed ID: 8324748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Status of the p53 tumor suppressor gene in human squamous carcinoma cell lines.
    Reiss M; Brash DE; Muñoz-Antonia T; Simon JA; Ziegler A; Vellucci VF; Zhou ZL
    Oncol Res; 1992; 4(8-9):349-57. PubMed ID: 1486218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic implications of p53 gene mutations in bladder tumors.
    Lorenzo-Romero JG; Salinas-Sánchez AS; Giménez-Bachs JM; Sánchez-Sánchez F; Escribano-Martínez J; Segura-Martín M; Hernandez-Millán IR; Virseda-Rodríguez JA
    J Urol; 2003 Feb; 169(2):492-9. PubMed ID: 12544295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequent association of p53 gene mutation in invasive bladder cancer.
    Fujimoto K; Yamada Y; Okajima E; Kakizoe T; Sasaki H; Sugimura T; Terada M
    Cancer Res; 1992 Mar; 52(6):1393-8. PubMed ID: 1540947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific p53 gene mutations in urinary bladder epithelium after the Chernobyl accident.
    Yamamoto S; Romanenko A; Wei M; Masuda C; Zaparin W; Vinnichenko W; Vozianov A; Lee CC; Morimura K; Wanibuchi H; Tada M; Fukushima S
    Cancer Res; 1999 Aug; 59(15):3606-9. PubMed ID: 10446970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A hot spot for p53 mutation in transitional cell carcinoma of the bladder: clues to the etiology of bladder cancer.
    Xu X; Stower MJ; Reid IN; Garner RC; Burns PA
    Cancer Epidemiol Biomarkers Prev; 1997 Aug; 6(8):611-6. PubMed ID: 9264274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.
    Modi S; Kubo A; Oie H; Coxon AB; Rehmatulla A; Kaye FJ
    Oncogene; 2000 Sep; 19(40):4632-9. PubMed ID: 11030152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma.
    Zhang ZT; Pak J; Shapiro E; Sun TT; Wu XR
    Cancer Res; 1999 Jul; 59(14):3512-7. PubMed ID: 10416618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines.
    Wasielewski M; Elstrodt F; Klijn JG; Berns EM; Schutte M
    Breast Cancer Res Treat; 2006 Sep; 99(1):97-101. PubMed ID: 16541312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel p21WAF1/CIP1 mutations in superficial and invasive transitional cell carcinomas.
    Malkowicz SB; Tomaszewski JE; Linnenbach AJ; Cangiano TA; Maruta Y; McGarvey TW
    Oncogene; 1996 Nov; 13(9):1831-7. PubMed ID: 8934528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations of the p53 tumor suppressor gene during mouse skin tumor progression.
    Ruggeri B; Caamano J; Goodrow T; DiRado M; Bianchi A; Trono D; Conti CJ; Klein-Szanto AJ
    Cancer Res; 1991 Dec; 51(24):6615-21. PubMed ID: 1742735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.
    Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H
    Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.